Molecular Imaging Advances in Endometriosis: The Promise of Radiopharmaceuticals
Molecules · 2025
DOI: 10.3390/molecules31010093 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2025. Verfasst von Rebecca Napolitano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy. Hauptthemen laut MEDLINE: Endometriosis, Radiopharmaceuticals, Molecular Imaging. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Endometriosis is a highly prevalent, chronic gynecological disorder characterized by the ectopic presence of endometrial-like tissue, driving significant morbidity and chronic pelvic pain. Pathologically, it is increasingly recognized as a fibro-inflammatory condition involving extensive tissue remodeling and fibrosis. Current conventional imaging modalities, including ultrasound and MRI, are primarily morphological, while standard molecular imaging using Positron Emission Tomography (PET) tracers has shown limited diagnostic utility. [18F]Fluorodeoxyglucose (FDG) suffers from high physiological uptake in pelvic organs and inconsistent detection of lesions. Receptor-based tracers like [68Ga]Ga-DOTATATE have demonstrated uncertain efficacy. In contrast, radiopharmaceuticals targeting the Fibroblast Activation Protein (FAP) offer a promising molecular approach. FAP is specifically overexpressed by activated fibroblasts present in the stroma of endometriotic lesions, correlating significantly with tissue fibrosis (collagen content) and local immune infiltration (e.g., CD68 macrophages). This comprehensive review analyzes the landscape of radiopharmaceuticals for endometriosis imaging, contrasting the specific limitations of traditional metabolic and receptor agents with the molecular rationale and emerging evidence supporting the use of FAP Inhibitors (FAPI), positioning them as crucial, non-invasive tools for the future diagnosis and management of this challenging disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medicine, University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy.
- Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy.
- Department of Environmental and Prevention Sciences, University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara, Italy.
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.
- Department of Nuclear Medicine, Istanbul Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Fahrettin Kerim Gökay 161, Kadıköy, 34722 İstanbul, Turkey.
ORCID-Profile: Giorgia Speltri, Petra Martini, Licia Uccelli, Luca Urso, Luca Filippi, Hatice Uslu, Alessandra Boschi
Zitieren
APA
Napolitano, R., Speltri, G., Martini, P., Porto, F., Marvelli, L., Niorettini, A., Uccelli, L., Urso, L., Filippi, L., Uslu, H., Canitez, B., Kösem, H. A., & Boschi, A. (2025). Molecular Imaging Advances in Endometriosis: The Promise of Radiopharmaceuticals. Molecules. https://doi.org/10.3390/molecules31010093
Vancouver
Napolitano R, Speltri G, Martini P, Porto F, Marvelli L, Niorettini A, et al. Molecular Imaging Advances in Endometriosis: The Promise of Radiopharmaceuticals. Molecules. 2025. doi:10.3390/molecules31010093
BibTeX
@article{Napolitano2025,
author = {Napolitano, Rebecca and Speltri, Giorgia and Martini, Petra and Porto, Francesca and Marvelli, Lorenza and Niorettini, Alessandro and Uccelli, Licia and Urso, Luca and Filippi, Luca and Uslu, Hatice and Canitez, Burak and Kösem, Hamza Alperen and Boschi, Alessandra},
title = {Molecular Imaging Advances in Endometriosis: The Promise of Radiopharmaceuticals},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules31010093}
}
EUVIMED